Greg Madison of Shield Therapeutics: There is a very substantial market opportunity for Accrufer®
Greg Madison CEO of discusses their strong Q2 which showed total prescriptions for Accrufer® increase by 50% compared to Q1 and says, “There is a very substantial market opportunity for Accrufer® and we are looking to identify ways to maximise the momentum we are building in order to further drive continued Accrufer® growth”
Highlights
Snapshot of increasing Q2 KPI metrics - (all comparisons are sequential to Q1 2023)
· Increase in total prescriptions -- Over 15,800, grew 50%
o May grew 28% vs April, and June grew 30% vs May
· Increase in new prescriptions - grew 63%
· Increase in first time writers - grew 157%
· Positive clinical experiences leading to follow-up prescriptions
o High percentage of repeat writers - 73% of the HCP's who wrote an Rx in Q1 '23 wrote another prescription in Q2
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.